Related references
Note: Only part of the references are listed.De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
Debu Tripathy et al.
ONCOLOGIST (2020)
The mutational constraint spectrum quantified from variation in 141,456 humans
Konrad J. Karczewski et al.
NATURE (2020)
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Pingping Mao et al.
CLINICAL CANCER RESEARCH (2020)
The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer
Sean Seltzer et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2020)
Genomic characterization of metastatic breast cancers
Francois Bertucci et al.
NATURE (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
Lindsay Angus et al.
NATURE GENETICS (2019)
Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer
E. S. Sokol et al.
ANNALS OF ONCOLOGY (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies
Utthara Nayar et al.
NATURE GENETICS (2019)
ClinVar: improving access to variant interpretations and supporting evidence
Melissa J. Landrum et al.
NUCLEIC ACIDS RESEARCH (2018)
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Francisco Sanchez-Vega et al.
CELL (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors
Ryan N. Ptashkin et al.
JAMA ONCOLOGY (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Alexandra Thomas et al.
ONCOIMMUNOLOGY (2018)
Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010
Judith A. Malmgren et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
PRKCI promotes immune suppression in ovarian cancer
Sharmistha Sarkar et al.
GENES & DEVELOPMENT (2017)
Integrative clinical genomics of metastatic cancer
Dan R. Robinson et al.
NATURE (2017)
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Viktor A. Adalsteinsson et al.
NATURE COMMUNICATIONS (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy
Jun Qian et al.
SCIENTIFIC REPORTS (2017)
Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States
Angela B. Mariotto et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2017)
Validation of OncoPanel A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer
Elizabeth P. Garcia et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)
Timing, rates and spectra of human germline mutation
Raheleh Rahbari et al.
NATURE GENETICS (2016)
MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
Andrew R. Green et al.
BRITISH JOURNAL OF CANCER (2016)
c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/β-Catenin/Axin2 Pathway
Yihao Li et al.
CANCER RESEARCH (2016)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira et al.
NATURE COMMUNICATIONS (2016)
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
Celine Lefebvre et al.
PLOS MEDICINE (2016)
deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution
Rachel Rosenthal et al.
GENOME BIOLOGY (2016)
f Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette M. Sholl et al.
JCI INSIGHT (2016)
Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
D. J. A. Lobbezoo et al.
BRITISH JOURNAL OF CANCER (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Global gene expression profiling reveals a suppressed immune response pathway associated with 3q amplification in squamous carcinoma of the lung
Jun Qian et al.
GENOMICS DATA (2015)
Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients
Laura E. MacConaill et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers
Huiling Xu et al.
BREAST CANCER RESEARCH (2011)
Immortal time bias in observational studies of drug effects
Samy Suissa
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance
SL Deming et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
